Good day, The role of biostatistics in drug and medical device development is very important, particularly for clinical trial design, biomarker validation, and regulatory approval. An appropriate case in point on biostatistics assisted health enhancement. A powerful example included biostatistical modeling during the creation of an innovative biomarker for neurodegenerative disease. In one study aimed at Alzheimer's disease, researchers used longitudinal statistical models to analyze cerebrospinal fluid (CSF) and imaging biomarkers. Using Bayesian hierarchical models and survival analysis, they determined patterns that correlated the progression of each biomarker with cognitive decline. The statistical validation of these biomarkers allowed pharma companies to stratify by these measurable markers participants in clinical trials, making drug trials more efficient and targeted. This work had an incredibly powerful impact. Because biomarkers can predict the clinical outcome (also known as a surrogate endpoint), there has also been a drive to use biomarkers to enable faster early phase clinical trials and better patient selection criteria. This shortened trial lengths and improved the chances of success for disease modifying therapies. This paradigm ultimately informed both FDA and EMA regulatory guidance, as well as the trajectory of modern neurodegenerative drug development.